Seasonal ranking highlights higher-risk cities where heat, humidity, rainfall, and standing water can drive mosquito activityNEW ORLEANS, June 4, 2026 /PRNewswire/ -- As mosquito...
Now available nationwide ahead of peak mosquito season, LIV 2.0 delivers scientifically proven, EPA-registered on-demand protection for backyards, restaurants, resorts and senior living.BEDFORD, Mass.,...
ohDEER Portland ME marks the company's twenty-first location.PORTLAND, Maine, June 2, 2026 /PRNewswire/ -- ohDEER, a leading provider of all-natural deer, tick, mosquito, and...
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.
TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...
Tech-driven outdoor cooling company uses smart tools and intuitive design to modernize how consumers choose and use misting systems
DALLAS, July 14, 2025 /PRNewswire/ --...
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC).
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.